Osimertinib used as a consolidation therapy for post-CCRT unresectable stage III NSCLC with EGFR mutations currently under investigation in the LAURA trial [36], and the results of the LAURA trial may support using consolidation osimertinib in the future. This evidence concerns the gene EGFR and non-small cell lung carcinoma.